Jennifer Schneider Elected to Vertex Board of Directors
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive. She co-founded and serves as Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural America. Prior to founding Homeward in 2022, Dr. Schneider served as President and Chief Medical Officer of Livongo Health, a biotechnology company serving people with chronic conditions including diabetes, hypertension, obesity and behavioral health issues. While there, she led the company through the largest consumer digital health Initial Public Offering in history and the industry’s largest merger between Livongo and Teladoc Health. She also served as Chief Medical Officer of Castlight Health, a health care navigation company for self-insured companies.
“We’re thrilled to have Jenny join the Vertex Board. She brings a unique perspective and experience as a physician-executive with deep expertise in health systems, policy and reimbursement, as well as technology-enabled health care. As Vertex enters a new era of commercial diversification, Jenny’s decades-long work in population health and reimbursement, her data and analytical skills, and ability to apply emerging health technologies to complex problems will help Vertex fulfill its mission to serve more patients across new diseases and therapeutic modalities,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex.
“I am honored to join the Vertex Board at this incredibly exciting time in the company’s history with its commitment to innovation yielding extraordinary achievements in cystic fibrosis, sickle cell disease, and beta thalassemia, among others,” said Jennifer Schneider, M.D., M.S. “I look forward to working with my fellow directors to support the company’s continued innovation and growth.”
Prior to her industry roles, Dr. Schneider conducted research in health services at Stanford University and worked as a physician in internal medicine at various hospitals. She currently serves on the Board of Directors of Jasper Health and Maven Health. Dr. Schneider holds a Bachelor of Arts in biology from the College of the Holy Cross, a Doctorate in Medicine from Johns Hopkins University School of Medicine, and a Master of Science in health services research from Stanford University.
The addition of Dr. Schneider brings Vertex’s board of directors to 11 members, nine of whom are independent and 45% of whom are women.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.
(VRTX-GEN)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513941236/en/
Contact information
Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com
Susie Lisa, CFA: +1 617-341-6108
or
Manisha Pai: +1 617-961-1899
or
Miroslava Minkova: +1 617-341-6135
Media:
mediainfo@vrtx.com
or
U.S.: +1 617-341-6992
or
Heather Nichols: +1 617-839-3607
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ansys and IonQ Are Bringing the Power of Quantum to the $10 Billion Dollar Computer-Aided Engineering Industry6.11.2024 22:10:00 CET | Press Release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, and Ansys (Nasdaq: ANSS), have joined forces to integrate quantum computing into the $10B computer-aided engineering (CAE) industry.* Together, IonQ and Ansys aim to accelerate simulation, expand high-fidelity design exploration, and reduce product development timelines, enabling faster market entry for innovative products. This partnership aims to make simulation accessible to both quantum experts and non-experts, with the goal of enhancing enterprise value and streamlining product development processes. Ansys solutions are used in product development across industries and account for a significant portion of all modeling and simulation in the CAE market. As IonQ’s quantum computers advance and outpace classical systems on specific tasks, integrating them with Ansys’ technology for complex simulations will open the door to new discoveries and innovations. With these advancements, Ansys will gain access to critical infrastr
Pure Lithium Announces New York Series B Roadshow6.11.2024 21:10:00 CET | Press Release
Pure Lithium Corporation, a disruptive Boston-based vertically-integrated lithium metal battery technology company, is pleased to announce that it will conduct a roadshow in New York the week of November 18, 2024 to promote its $75M to $100M Q1 2025 Series B fundraise. The funds will support the scale-up of the Company’s technology towards commercial lithium metal battery production and a potential Initial Public Offering of the company. Lithium metal is the "holy grail" of energy storage, a step change beyond today's lithium-ion battery. It does not require graphite, nickel, cobalt and manganese, eliminating dependence on China and enabling local battery hubs in favorable jurisdictions for the first time ever. Since opening its Boston lab in January of 2021, Pure Lithium has made impressive strides towards commercializing the lithium metal battery. This year, the Company raised $20M in its Series A.5 with Oxy Low Carbon Ventures as the lead investor. Major progress has been made on a
Perma-Pipe International Holdings, Inc. Announces $15 Million in Contract Awards in the Americas and Middle East Regions6.11.2024 20:01:00 CET | Press Release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced $6 million in new project awards in the MENA region. Additionally, the company announced $9 million in new project awards in the Americas, demonstrating continual improvement in the region. These new project awards will utilize Perma-Pipe’s anti-corrosion coatings capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. These new project awards further complement our backlog, which has experienced considerable growth. Backlog was $75.0 million at July 31, 2024 and is now in excess of $100.0 million. Marc Huber, Sr. Vice President for Perma-Pipe’s Americas region, commented, “We are delighted with these awards which demonstrate the buoyancy in the Americas market and the continual strengthening of our position in the USA and Canada.” Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “The latest awards in MENA largely
Mouser Electronics Examines the Human-Centric Revolution of Industry 5.06.11.2024 18:11:00 CET | Press Release
Mouser Electronics, Inc., the global authorized distributor renowned for providing the latest in electronic components and industrial automation solutions, today unveiled the newest chapter in its Empowering Innovation Together (EIT) technology series, which focuses on the emerging landscape of Industry 5.0. In this next phase of industrialization, human, environmental, and social considerations will factor into the advanced technology, robotics, and smart machines on the factory floor of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241106421709/en/ For the last several decades, the manufacturing world has been integrating robots into factory control systems—a move compared to a fourth industrial revolution and named Industry 4.0. Now, Industry 5.0 puts people at the heart of manufacturing bringing technology and humanity closer together. (Graphic: Business Wire) Building on the technological advancements of In
Building a World-Class Synthetic Biology Lab: Asymchem’s Self-Developed STAR System Empowers Protein Design6.11.2024 17:00:00 CET | Press Release
Asymchem (stock code: 002821.SZ/6821.HK), a leading global contract development and manufacturing organization (CDMO), has created an artificial intelligence (AI) platform to address key challenges in protein design. This platform, known as STAR (Sequence Recommendation via Artificial Intelligence), was successfully developed by Asymchem’s Center of Synthetic Biology Technology (CSBT) and AI team. The team published a paper titled “STAR: A Web Server for Assisting Directed Protein Evolution with Machine Learning” in ACS Omega, detailing the system’s ability to integrate multiple machine learning models and sequence encoding methods. One major challenge in protein engineering is the number of mutations that need to be generated and screened. This can take anywhere from 3 to 6 months. STAR dramatically accelerates this process. By leveraging machine learning, the platform quickly identifies critical regions for mutation. This reduces the number of experimental samples to just a few hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom